Last reviewed · How we verify

insulin degludec + liraglutide

Hospital Universitario San Ignacio · FDA-approved active Small molecule

insulin degludec + liraglutide is a Basal insulin + GLP-1 receptor agonist combination Small molecule drug developed by Hospital Universitario San Ignacio. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: ideglira.

This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism.

This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism. Used for Type 2 diabetes mellitus.

At a glance

Generic nameinsulin degludec + liraglutide
Also known asideglira
SponsorHospital Universitario San Ignacio
Drug classBasal insulin + GLP-1 receptor agonist combination
TargetInsulin receptor (degludec); GLP-1 receptor (liraglutide)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin degludec is a long-acting basal insulin that provides steady background glucose control over 24+ hours. Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety. Together, they address both fasting and postprandial hyperglycemia while supporting weight loss.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about insulin degludec + liraglutide

What is insulin degludec + liraglutide?

insulin degludec + liraglutide is a Basal insulin + GLP-1 receptor agonist combination drug developed by Hospital Universitario San Ignacio, indicated for Type 2 diabetes mellitus.

How does insulin degludec + liraglutide work?

This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism.

What is insulin degludec + liraglutide used for?

insulin degludec + liraglutide is indicated for Type 2 diabetes mellitus.

Who makes insulin degludec + liraglutide?

insulin degludec + liraglutide is developed and marketed by Hospital Universitario San Ignacio (see full Hospital Universitario San Ignacio pipeline at /company/hospital-universitario-san-ignacio).

Is insulin degludec + liraglutide also known as anything else?

insulin degludec + liraglutide is also known as ideglira.

What drug class is insulin degludec + liraglutide in?

insulin degludec + liraglutide belongs to the Basal insulin + GLP-1 receptor agonist combination class. See all Basal insulin + GLP-1 receptor agonist combination drugs at /class/basal-insulin-glp-1-receptor-agonist-combination.

What development phase is insulin degludec + liraglutide in?

insulin degludec + liraglutide is FDA-approved (marketed).

What are the side effects of insulin degludec + liraglutide?

Common side effects of insulin degludec + liraglutide include Nausea, Hypoglycemia, Vomiting, Diarrhea, Headache, Injection site reactions.

What does insulin degludec + liraglutide target?

insulin degludec + liraglutide targets Insulin receptor (degludec); GLP-1 receptor (liraglutide) and is a Basal insulin + GLP-1 receptor agonist combination.

Related